Wealth Effects LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Wealth Effects LLC

$269 Million
Q1 2024

A detailed history of Wealth Effects LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Wealth Effects LLC holds 164,460 shares of ARWR stock, worth $4.27 Million. This represents 1.75% of its overall portfolio holdings.

Number of Shares

164,460

Previous 161,850 1.61%

Holding current value

$4.27 Million

Previous $4.95 Million 5.03%

% of portfolio

1.75%

Previous 1.87%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	BUY	$27.21 - $39.48 $71,018 - $103,042	2,610 Added 1.61%	164,460 $4.7 Million
Q4 2023 Jan 29, 2024	SELL	$21.2 - $31.03 $61,480 - $89,987	-2,900 Reduced 1.76%	161,850 $4.95 Million
Q3 2023 Oct 16, 2023	BUY	$26.2 - $36.08 $18,340 - $25,256	700 Added 0.43%	164,750 $4.43 Million
Q2 2023 Jul 18, 2023	BUY	$25.16 - $41.38 $182,158 - $299,591	7,240 Added 4.62%	164,050 $5.85 Million
Q1 2023 May 04, 2023	BUY	$23.68 - $38.51 $28,179 - $45,826	1,190 Added 0.76%	156,810 $3.98 Million

Q4 2022 Feb 02, 2023	SELL	$28.0 - $40.56 $28,000 - $40,560	-1,000 Reduced 0.64%	155,620 $6.31 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $88,890 - $144,930	3,000 Added 1.95%	156,620 $5.18 Million
Q2 2022 Aug 03, 2022	BUY	$27.79 - $50.61 $94,486 - $172,074	3,400 Added 2.26%	153,620 $5.41 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $168,781 - $298,072	4,260 Added 2.92%	150,220 $6.91 Million
Q4 2021 Feb 09, 2022	BUY	$58.09 - $82.51 $8.48 Million - $12 Million	145,960 New	145,960 $9.68 Million

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

88.5M

Call Options Held

905K

Put Options Held

387K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.75B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealth Effects LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealth Effects LLC with notifications on news.

Account

Wealth Effects LLC Arrowhead Pharmaceuticals, Inc. Transaction History